Pilot-Scale Study Of Human Plasma Proteomics Identifies ApoE And IL33 As Markers In Atopic Asthma
Authors Bhowmik M, Majumdar S, Dasgupta A, Gupta Bhattacharya S, Saha S
Received 8 April 2019
Accepted for publication 12 August 2019
Published 20 September 2019 Volume 2019:12 Pages 273—283
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 3
Editor who approved publication: Dr Amrita Dosanjh
Moumita Bhowmik,1,* Sreyashi Majumdar,2,* Angira Dasgupta,3 Swati Gupta Bhattacharya,1 Sudipto Saha2
1Division of Plant Biology, Bose Institute, Kolkata, West Bengal, India; 2Division of Bioinformatics, Bose Institute, Kolkata, West Bengal, India; 3BR Singh Hospital and Centre for Medical Education and Research, Kolkata, West Bengal, India
*These authors contributed equally to this work
Correspondence: Swati Gupta Bhattacharya
Division of Plant Biology, Main Campus, Bose Institute, 93/1 APC Road, Kolkata 700009, India
Tel +91 33 2303 1129
Division of Bioinformatics, Centenary Campus, Bose Institute, P-1/12 CIT Scheme VII-M, Kolkata 700054, India
Tel +91 33 2569 3333
Background: The pathobiology of atopic asthma is complex and the symptoms similar to other respiratory diseases. As such, identification of biomarkers of atopic asthma is of prime importance for better diagnosis and control of the disease.
Objectives: We sought to study the changes in plasma proteome and cytokine-expression profile across healthy and atopic asthmatics for identifying biomarkers and exploring aberrant pathways for atopic asthma.
Methods: A pilot-scale study in humans was performed to identify differentially expressed proteins in blood plasma of healthy controls (n=5) and treatment-naïve atopic asthma patients (n=5) using quantitative label-free liquid chromatography–tandem mass spectrometry proteomics and ELISA.
Results: Mass spectrometry–based proteomic analysis revealed ApoE to be significantly downregulated in atopic asthmatics compared to healthy volunteers. Decreased expression of ApoE in atopic asthmatics was validated by immunoblotting (50.74% decrease). Comparison with atopic asthmatics and COPD patients showed that ApoE was decreased (36.33%) in atopic asthma compared to COPD. IL33 was significantly upregulated in atopic asthmatics compared to healthy subjects (3.84-fold).
Conclusion: ApoE was downregulated and IL33 upregulated in atopic asthma patients compared to healthy volunteers. These two proteins’ profiles were distinct in atopic asthma from healthy and COPD plasma samples. Differential expression of these proteins could serve as a probable candidate for a two-protein classifier–based prognostic biomarker of atopic asthma.
Keywords: atopic asthma, LC-MS/MS, apolipoprotein E, ApoE, interleukin 33, IL33, biomarkers
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]